Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT06227910 Sponsor: Takeda Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT06227910
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Crohn's disease (CD) for at least 3 months before the screening visit, confirmed by a camera examination of the gut and a tissue sample analysis.
  • Your Crohn's disease is considered moderately to severely active, based on a specific scoring system called the CDAI (with a score between 220 and 450).
  • There is visible inflammation in the lining of your gut, confirmed by a specialist review of your camera examination results.
  • Previous treatments for your Crohn's disease — such as steroids, immune-suppressing medications, or biologic therapies — have not worked well enough, have stopped working, or you were unable to tolerate them.

Who may not be able to join:

  • You have been diagnosed with ulcerative colitis or a form of bowel disease that doctors have not been able to clearly classify.
  • You have had an infection recently that required treatment with intravenous (drip) antibiotics or antifungals in the last 30 days, or oral/injected antibiotics in the last 14 days.
  • You currently have an active infection, had a significant infection in the last 30 days before screening, or have a long-term ongoing infection.
  • You have a history of shingles that came back more than once or spread widely through your body, or a history of a widespread herpes simplex infection (even a single episode).
  • You currently have certain serious complications of Crohn's disease, such as an abscess (a pocket of infection in the abdomen or around the back passage), a bowel blockage causing symptoms, large sections of the bowel missing, a severely inflamed colon, or any other complication that might require surgery during the study (confirm with trial site).
  • You have a stoma bag or a surgically created internal pouch (ileoanal pouch).
  • Your kidneys are severely affected, meaning they are working at less than 30% of normal function.
  • You have severe liver disease (known as Child-Pugh Class C).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Study Director, Takeda

Phone: +1-877-825-3327

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
2 January 2025
Est. completion
8 June 2027

Where this trial is recruiting

🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇭🇷 Croatia 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇳🇴 Norway 🇵🇱 Poland 🇵🇹 Portugal 🇸🇮 Slovenia 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 12; Percentage of Participants Exhibiting an Endoscopic Response Based on Simple Endoscopic Score for CD (SES-CD) at Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov